There is a vital need for quantitative assessment of tumor burden and cancer therapy response by in vivo imaging. Computed tomography (CT) and standard magnetic resonance imaging (MRI) cannot provide information on the molecular, biochemical and physiologic properties of cancer tissues, and may also fail to specifically distinguish viable tumor from benign conditions or necrotic tumor. Therefore, novel quantitative imaging techniques and protocols are needed to reveal biomarkers of molecular events induced by cancer therapy. In particular, early imaging of molecularly targeted pathways predicted to be essential for effective cancer therapy is highly likely to play a key role in patient management in the future. Development and use of quantitative imaging for early therapy assessment will greatly facilitate patient management, by sparing patients from weeks or months of toxicity and ineffective treatment. Additionally with the increasing rate of therapy development and related therapy trials, the development of minimally invasive, yet specific and accurate measurements of early therapeutic response has become of critical importance. Because none of the currently available imaging technologies can provide all of the needed information, there is an important trend to combine information from two or more imaging techniques. This need for multimodality imaging has led to a UPCI decision to combine two existing CCSG-funded shared facilities (MRI and PET), and to add a third modality (optical small animal imaging) to create a new, integrated UPCI shared facility, the In Vivo Imaging Facility (IVIF). In addition, the IVIF also incorporates the NCI-funded (CCSG supplement) Imaging Response Assessment Team (IRAT) program, which integrates the clinical research components of the IVIF. The IVIF provides expertise, to most of the CCSG programs of UPCI, in preclinical, translational, and clinical imaging using x-ray, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and optical imaging modalities. The goals of the facility are 1) to provide preclinical assessment of biomarker expression throughout cancer treatment, 2) to provide methods for monitoring biological therapy, 3) to facilitate protocol development for cancer detection, diagnosis, and staging and 4) to advance methods for evaluating early therapy response prognosis following treatment. The IVIF has already made significant contributions to UPCI research by providing non-invasive imaging biomarkers for tumor diagnosis, staging, and prognosis in addition to implementation of protocols for early therapy response assessment. The IVIF has a broad scope and is integral to the Cancer Epidemiology and Prevention Program (e.g. for screening for lung lesions in heavy smokers). The services provided incorporate a multi-modality approach and include measurements of a number of biomarkers for the early evaluation of new therapies, including: 1) tumor volume measurement and Response Evaluation Criteria in Solid Tumors (RECIST) assessment or tumor growth analysis (MRI, PET, &Optical);response to cancer therapy analysis 2) tumor glucose metabolism, cell proliferation, and apoptosis (F-18 FDG PET, F-18 FMISO and F-18 ML-10);3) tumor cell proliferation (F-18 FLT PET);4) tumor capillary transfer rates (MRI);5) spectroscopic analyses for total choline (MRI), citrate, and intracellular sodium (MRI);6) synthesis of targeted contrast agents (MRI, PET, and Optical);7) cell labeling and tracking (MRI &Optical);and 8) custom methods development (MRI, PET, &Optical).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol :
Concha-Benavente, Fernando; Srivastava, Raghvendra M; Trivedi, Sumita et al. (2016) Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 76:1031-43
Posluszny, Donna M; Dew, Mary Amanda; Beckjord, Ellen et al. (2016) Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey. J Health Psychol 21:2357-66
Vyas, Avani R; Moura, Michelle B; Hahm, Eun-Ryeong et al. (2016) Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem 117:2482-95
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Chen, Mingqing; Sun, Fan; Han, Lei et al. (2016) Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 7:33363-73
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2016) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res :
Delgado, Evan; Boisen, Michelle M; Laskey, Robin et al. (2016) High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol 141:348-56
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa et al. (2016) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 22:2855-64
Beumer, Jan H; Ding, Fei; Tawbi, Hussein et al. (2016) Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol 34:110-6

Showing the most recent 10 out of 885 publications